Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201566152926595892
   PubMedGoogle Scholar
• FletcherCDThe evolving classification of soft tissue tumours – an update based on the new 2013 WHO classificationHistopathology201464121124164390
   PubMed Web of Science ®Google Scholar
• SchwartzGKTrabectedin and the L-Sarcomas: a decade-long odysseyJ Clin Oncol201634876977126371135
   PubMed Web of Science ®Google Scholar
• DucimetièreFLurkinARanchère-VinceDIncidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testingPLoS One201168e2029421826194
   PubMed Web of Science ®Google Scholar
• The ESMO/European Sarcoma Network Working GroupSoft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii102iii11225210080
   PubMed Web of Science ®Google Scholar
• NussbaumDPRushingCNLaneWOPreoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology databaseLancet Oncol201617796697527210906
   PubMedGoogle Scholar
• MastrangeloGCoindreJMDucimetièreFIncidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regionsCancer201211865339534822517534
   PubMedGoogle Scholar
• JudsonIVerweijJGelderblomHDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialLancet Oncol20141541542324618336
   PubMed Web of Science ®Google Scholar
• García-Del-MuroXLópez-PousaAMaurelJSpanish Group for Research on SarcomasRandomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish group for research on sarcomas studyJ Clin Oncol2011292528253321606430
   PubMed Web of Science ®Google Scholar
• Le CesneAAntoineESpielmannMHigh-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomasJ Clin Oncol1995137160016087541449
   PubMed Web of Science ®Google Scholar
• Van der GraafWTBlayJYChawlaSPPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• SchöffskiPMakiRItalianoARandomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI)J Clin Oncol201533
   Google Scholar
• DemetriGDvon MehrenMJonesRLEfficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trialJ Clin Oncol201634878679326371143
   PubMed Web of Science ®Google Scholar
• DemetriGDChawlaSPvon MehrenMEfficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedulesJ Clin Oncol200927254188419619652065
   PubMed Web of Science ®Google Scholar
• KhalifaJOualiMChaltielLEfficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma GroupBMC Cancer20151570026472661
   PubMed Web of Science ®Google Scholar
• Le CesneACrestaSMakiRGA retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomasEur J Cancer201248163036304422749255
   PubMed Web of Science ®Google Scholar
• SanfilippoRDileoPBlayJYTrabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer NetworkAnticancer Drugs201526667868125763543
   PubMed Web of Science ®Google Scholar
• De SanctisRMarrariAMarchettiSEfficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcomaDrug Des Devel Ther201527957855791
   Google Scholar
• SingerSAntonescuCRRiedelEBrennanMFHistologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcomaAnn Surg2003238335837014501502
   PubMed Web of Science ®Google Scholar
• CragoAMSingerSClinical and molecular approaches to well differentiated and dedifferentiated liposarcomaCurr Opin Oncol201123437337821552124
   PubMed Web of Science ®Google Scholar
• Dei TosAPDoglioniCPiccininSCoordinated expression and amplification of the MDM2, CDK4 and HMGI-C genes in atypical lipomatous tumoursJ Pathol2000190553153610727978
   PubMed Web of Science ®Google Scholar
• Meis-KindblomJMSjögrenHKindblomLGCytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosisVirchows Arch2001439214115111561754
   PubMedGoogle Scholar
• OlinerJDPietenpolJAThiagalingamSGyurisJKinzlerKWVogelsteinBOncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature199336228578608479525
   PubMedGoogle Scholar
• PatelSRBurgessMAPlagerCPapadpoulosNELinkeKABenjaminRSMyxoid liposarcoma. Experience with chemotherapyCancer1994744126512698055448
   PubMedGoogle Scholar
• CrozatAAmanPMandahlNRonDFusion of CHOP to a novel RNA-binding protein in human myxoid liposarcomaNature199336364306406448510758
   PubMed Web of Science ®Google Scholar
• Dal CinPSciotRPanagopoulosIAdditional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological featuresJ Pathol199718244374419306965
   PubMed Web of Science ®Google Scholar
• GebhardSCoindreJMMichelsJJPleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma GroupAm J Surg Pathol200226260161611979090
   PubMedGoogle Scholar
• BathanAJConstantinidouAPollackSMJonesRLDiagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variantsCurr Opin Oncol201325438438923635801
   PubMedGoogle Scholar
• FaridMOngWSTanMHThe influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine diseaseAm J Clin Oncol201336436837422772425
   PubMedGoogle Scholar
• De VitaAMercataliLRecineFCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasOnco Targets Ther20169126233624627785071
   PubMedGoogle Scholar
• MakiRGWathenJKPatelSRRandomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002J Clin Oncol20072542755276317602081
   PubMedGoogle Scholar
• Zewail-FooteMHurleyLHEcteinascidin 743: a minor groove alkyla-tor that bends DNA toward the major grooveJ Med Chem199942814931497
   Google Scholar
• PommierYKohlhagenGBaillyCWaringMMazumderAKohnKWDNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinataBiochemistry1996354113303133098873596
   PubMedGoogle Scholar
• D’IncalciMGalmariniCMA review of trabectedin (ET-743): a unique mechanism of actionMol Cancer Ther2010982157216320647340
   PubMed Web of Science ®Google Scholar
• FriedmanDHuZKolbEAGorfajnBScottoKWEcteinascidin-743 inhibits activated but not constitutive transcriptionCancer Res200262123377338112067978
   PubMed Web of Science ®Google Scholar
• ForniCMinuzzoMVirdisETrabectedin (ET-243) promotes differentiation in myxoid liposarcoma tumorsMol Cancer Ther20098244945719190116
   PubMed Web of Science ®Google Scholar
• GermanoGFrapolliRBelgiovineCRole of macrophage targeting in the antitumor activity of trabectedinCancer Cell201323224926223410977
   PubMed Web of Science ®Google Scholar
• GrossoFJonesRLDemetriGDEfficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyLancet Oncol20078759560217586092
   PubMed Web of Science ®Google Scholar
• PuchalskiTARyanDPGarcia-CarboneroRPharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicityCancer Chemother Pharmacol200250430931912357306
   PubMed Web of Science ®Google Scholar
• RyanDPSupkoJGEderJPPhase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesClin Cancer Res20017223124211234874
   PubMed Web of Science ®Google Scholar
• TwelvesCHoekmanKBowmanAPhase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumoursEur J Cancer200339131842185112932661
   PubMed Web of Science ®Google Scholar
• TaammaAMissetJLRiofrioMPhase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumorsJ Clin Oncol20011951256126511230466
   PubMed Web of Science ®Google Scholar
• YovineARiofrioMBlayJYPhase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patientsJ Clin Oncol200422589089914990645
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGManolaJPhase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapyJ Clin Oncol20042281480149015084621
   PubMed Web of Science ®Google Scholar
• Le CesneABlayJYJudsonIPhase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialJ Clin Oncol200523357658415659504
   PubMed Web of Science ®Google Scholar
• SamuelsBLChawlaSPatelSClinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program studyAnn Oncol20132461703170923385197
   PubMed Web of Science ®Google Scholar
• BlayJYItalianoARay-CoquardILong-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use programBMC Cancer2013136423388156
   PubMed Web of Science ®Google Scholar
• GronchiABuiBNBonvalotSPhase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcomaAnn Oncol201223377177621642514
   PubMed Web of Science ®Google Scholar
• GronchiAFerrariSQuagliuoloVFull-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: interim analysis of a prospective randomized trialPaper presented at: European Society for Medical Oncology (ESMO) 2016 CongressOctober 7–11, 2016Copenhagen
   Google Scholar
• LetsonGDMuro-CachoCAGenetic and molecular abnormalities in tumors of the bone and soft tissuesCancer Control20018323925111378650
   PubMedGoogle Scholar
• Geurts van KesselASimonsAComtessePPRing chromosomes in a malignant mesenchymomaCancer Genet Cytogenet1999109211912210087943
   PubMedGoogle Scholar
• IdaKKobayashiSTakiTEWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing’s sarcoma and primitive neuroectodermal tumorInt J Cancer19956345005047591257
   PubMedGoogle Scholar
• ThwayKNoujaimJJonesRLFisherCDermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategiesAnn Diagn Pathol201625647127806849
   PubMed Web of Science ®Google Scholar
• LarramendyMLMandahlNMertensFClinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomasHum Pathol199930101247125310534175
   PubMedGoogle Scholar
• MavrogenisAFBianchiGStavropoulosNAPapagelopoulosPJRuggieriPClinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft partsHippokratia201317429830225031505
   PubMedGoogle Scholar
• GleasonBCHornickJLInflammatory myofibroblastic tumours: where are we now?J Clin Pathol200861442843717938159
   PubMed Web of Science ®Google Scholar
• DonnerLRSilvaMTDobinSMSolitary fibrous tumor of the pleura: a cytogenetic studyCancer Genet Cytogenet1999111216917110347558
   PubMedGoogle Scholar
• FrickeAUllrichPVCimniakAFSynovial sarcoma microvesicles harbor the SYT-SSX fusion gene transcript: comparison of different methods of detection and implications in biomarker researchStem Cells Int20162016614604727069481
   PubMedGoogle Scholar
• BlayJYLeahyMGNguyenBBRandomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasEur J Cancer20145061137114724512981
   PubMed Web of Science ®Google Scholar
• KawaiAArakiNSugiuraHTrabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomized, open-label, phase 2 studyLancet Oncol201516440641625795406
   PubMed Web of Science ®Google Scholar
• HoiczykMGrabellusFPodleskaLTrabectedin in metastatic soft tissue sarcomas: role of pretreatment and ageInt J Oncol2013431232823652821
   PubMedGoogle Scholar
• ChaigneauLKalbacherEThiery-VuilleminAEfficacy of trabectedin in metastatic solitary fibrous tumorRare Tumors201133e2922066036
   PubMedGoogle Scholar
• Bui-NguyenBButrynskiJEPenelNEuropean Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC/STBSG) and the Sarcoma Alliance for Research through Collaboration (SARC)A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trialEur J Cancer201551101312132025912752
   PubMed Web of Science ®Google Scholar
• Martin-BrotoJPousaALde Las PeñasRRandomized Phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish group for research on sarcoma studyJ Clin Oncol201634192294230227185843
   PubMed Web of Science ®Google Scholar
• Yondelis^® summary of product characteristics Available from: www.ema.europa.eu/docs/en_GBAccessed March 3, 2016
   Google Scholar
• GrossoFDileoPSanfilippoRSteroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcomaEur J Cancer200642101484149016737808
   PubMed Web of Science ®Google Scholar
• Paz-AresLLópez-PousaAPovedaATrabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasoneInvest New Drugs201230272974020960029
   PubMed Web of Science ®Google Scholar
• GrossoFD’IncalciMCartoafaMA comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedinCancer Chemother Pharmacol20126961557156522484722
   PubMed Web of Science ®Google Scholar
• Le CesneARay-CoquardIDuffaudFFrench Sarcoma GroupFrench Sarcoma Group. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma GroupEur J Cancer201551674275025727882
   PubMed Web of Science ®Google Scholar
• Le CesneABlayJYDomontJInterruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trialLancet Oncol201516331231925680558
   PubMed Web of Science ®Google Scholar
• TapWDJonesRLVan TineBAOlaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialLancet20163881004348849727291997
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMvan OosteromATOosterhuisJWPrognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyJ Clin Oncol199917115015710458228
   PubMed Web of Science ®Google Scholar